Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Puma Biotechnology (NASDAQ: PBYI) has announced the approval of an inducement restricted stock unit award by its Compensation Committee. The award, covering 3,500 shares of Puma common stock, was granted to a new non-executive employee under the company's 2017 Employment Inducement Incentive Award Plan.
The restricted stock unit award features a three-year vesting schedule: one-third of shares vest on March 1, 2026 (first anniversary), followed by one-sixth of shares vesting every six months thereafter. The grant, approved on March 4, 2025, complies with Nasdaq Listing Rule 5635(c)(4) as an inducement for employment.
Puma Biotechnology (NASDAQ: PBYI) ha annunciato l'approvazione di un premio in azioni riservate da parte del suo Comitato di Compensazione. Il premio, che copre 3.500 azioni ordinarie di Puma, è stato assegnato a un nuovo dipendente non esecutivo nell'ambito del Piano di Incentivazione per l'Occupazione del 2017.
Il premio in azioni riservate prevede un programma di vesting di tre anni: un terzo delle azioni matura il 1° marzo 2026 (primo anniversario), seguito da un sesto delle azioni che maturano ogni sei mesi successivi. La concessione, approvata il 4 marzo 2025, è conforme alla Regola di Quotazione Nasdaq 5635(c)(4) come incentivo per l'occupazione.
Puma Biotechnology (NASDAQ: PBYI) ha anunciado la aprobación de un premio en unidades de acciones restringidas por parte de su Comité de Compensación. El premio, que cubre 3,500 acciones ordinarias de Puma, fue otorgado a un nuevo empleado no ejecutivo bajo el Plan de Incentivos de Empleo de 2017 de la compañía.
El premio en unidades de acciones restringidas cuenta con un programa de adquisición de derechos de tres años: un tercio de las acciones se adquiere el 1 de marzo de 2026 (primer aniversario), seguido de un sexto de las acciones que se adquieren cada seis meses después. La concesión, aprobada el 4 de marzo de 2025, cumple con la Regla de Cotización Nasdaq 5635(c)(4) como incentivo para el empleo.
푸마 생명공학 (NASDAQ: PBYI)는 보상 위원회에 의해 제한된 주식 단위 보상의 승인을 발표했습니다. 이 보상은 3,500 주의 푸마 보통주를 포함하며, 회사의 2017년 고용 유인 인센티브 상장 계획에 따라 새로운 비임원 직원에게 부여되었습니다.
제한된 주식 단위 보상은 3년의 베스팅 일정을 특징으로 하며: 2026년 3월 1일(첫 번째 기념일)에 3분의 1의 주식이 베스팅되고, 이후 매 6개월마다 6분의 1의 주식이 베스팅됩니다. 이 부여는 2025년 3월 4일에 승인되었으며, 고용에 대한 유인으로서 나스닥 상장 규칙 5635(c)(4)를 준수합니다.
Puma Biotechnology (NASDAQ: PBYI) a annoncé l'approbation d'une attribution d'unités d'actions restreintes par son Comité de Rémunération. Cette attribution, couvrant 3 500 actions ordinaires de Puma, a été accordée à un nouvel employé non exécutif dans le cadre du Plan d'Incentive à l'Emploi de 2017 de l'entreprise.
L'attribution d'unités d'actions restreintes présente un calendrier d'acquisition de droits de trois ans : un tiers des actions sera acquis le 1er mars 2026 (premier anniversaire), suivi d'un sixième des actions acquises tous les six mois par la suite. L'attribution, approuvée le 4 mars 2025, est conforme à la Règle de Cotation Nasdaq 5635(c)(4) en tant qu'incitation à l'emploi.
Puma Biotechnology (NASDAQ: PBYI) hat die Genehmigung eines Anreizprogramms für beschränkte Aktieneinheiten durch seinen Vergütungsausschuss bekannt gegeben. Die Auszeichnung, die 3.500 Aktien von Puma-Stammaktien umfasst, wurde einem neuen nicht-executiven Mitarbeiter im Rahmen des Anreizprogramms für Beschäftigung von 2017 gewährt.
Die beschränkte Aktieneinheitenauszeichnung sieht einen drei Jahre dauernden Vesting-Zeitplan vor: Ein Drittel der Aktien wird am 1. März 2026 (erster Jahrestag) fällig, gefolgt von einem Sechstel der Aktien, die alle sechs Monate danach fällig werden. Die Genehmigung, die am 4. März 2025 erteilt wurde, entspricht der Nasdaq-Listing-Regel 5635(c)(4) als Anreiz für die Beschäftigung.
- None.
- None.
The award was granted under Puma’s 2017 Employment Inducement Incentive Award Plan, which was adopted on April 27, 2017 and provides for the granting of equity awards to new employees of Puma. The restricted stock unit award vests over a three-year period, with one-third of the shares underlying the award vesting on the first anniversary of the award’s vesting commencement date, March 1, 2025, and one-sixth of the shares underlying the award vesting on each six-month anniversary of the vesting commencement date thereafter, subject to continued service. The award was granted as an inducement material to the new employee entering into employment with Puma, in accordance with Nasdaq Listing Rule 5635(c)(4).
About Puma Biotechnology
Puma Biotechnology, Inc. is a biopharmaceutical company with a focus on the development and commercialization of innovative products to enhance cancer care. Puma in-licensed the global development and commercialization rights to PB272 (neratinib, oral), in 2011. Neratinib, oral was approved by the
In September 2022, Puma entered into an exclusive license agreement for the development and commercialization of the anti-cancer drug alisertib, a selective, small molecule, orally administered inhibitor of aurora kinase A. Initially, Puma intends to focus the development of alisertib on the treatment of small cell lung cancer and breast cancer. In February 2024, Puma initiated ALISCA™-Lung1, a Phase II clinical trial of alisertib monotherapy for the treatment of patients with extensive-stage small cell lung cancer. In November 2024, Puma initiated ALISCA™-Breast1, a Phase II clinical trial of alisertib in combination with endocrine therapy for the treatment of patients with HER2-negative, HR-positive metastatic breast cancer.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250305993731/en/
Alan H. Auerbach or Mariann Ohanesian, Puma Biotechnology, Inc., +1 424 248 6500
info@pumabiotechnology.com
ir@pumabiotechnology.com
Source: Puma Biotechnology, Inc.
FAQ
What is the size of Puma Biotechnology's (PBYI) latest restricted stock unit award?
When will the PBYI restricted stock units begin vesting?
What is the vesting schedule for PBYI's March 2025 inducement award?
Under which plan was the PBYI inducement award granted?
